RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Background: Inflammatory bowel disease (IBD) is a disease of unknown origin that causes chronic inflammation of the intestines and is classified as either ulcerative colitis or Crohn’s disease. The incidence and prevalence of IBD in Korea have been rapidly increasing during the past three decades. This paper describes the current status of IBD in Korea.
Current Concepts: Compared with western countries, genotypes and phenotypes of IBD in Korea demonstrate some distinct features, which may have an impact on the diagnosis, treatment, and prognosis of IBD. We continue to experience some difficulties in making early and accurate diagnoses of IBD in Korea due to a low awareness of the disease and the high prevalence of infectious enterocolitis, such as intestinal tuberculosis, which needs to be differentiated from IBD. The treatment of IBD can be influenced by differences in genetic, environmental, and social factors. NUDT15 variants limit the use of thiopurines. Infectious diseases, including tuberculosis, hepatitis B, and cytomegalovirus colitis, are usually more common in Asia than in western countries and can adversely influence the management of IBD. Biologic agents, which have changed the treatment paradigm of IBD, are equally efficacious in Asian patients as in Western patients. However, their use is limited due to a strict Korean government health insurance reimbursement policy. The prognosis of ulcerative colitis in Korea may be better than that in western countries, as indicated by a lower colectomy rate. However, this difference is less distinct in Crohn’s disease.
Discussion and Conclusion: IBD in Korea differs from that in western countries in many respects. With rapid increase in the prevalence of IBD in Korea, medical costs for IBD are expected to become a significant financial burden. Koreans need to be prepared for this eventuality.

참고문헌 (Reference)

1 이광재, "염증성 장질환의 약물요법" 대한의사협회 58 (58): 57-63, 2015

2 Kim JW, "Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea : a nationwide populationbased study" 33 : 847-854, 2018

3 Cao Q, "Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease" 79 : 58-63, 2009

4 Lee HS, "The risk of colorectal cancer in inflammatory bowel disease : a hospital-based cohort study from Korea" 50 : 188-196, 2015

5 Leong RW, "The epidemiology and phenotype of Crohn's disease in the Chinese population" 10 : 646-651, 2004

6 Seo H, "Temporal trends in the misdiagnosis rates between Crohn's disease and intestinal tuberculosis" 23 : 6306-6314, 2017

7 Park SH, "Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis" 58 : 3592-3599, 2013

8 Hong SN, "Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease : a nationwide population-based study in South Korea" 45 : 253-263, 2017

9 Lee HS, "Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis" 22 : 912-918, 2016

10 Soo-Kyung Park, "Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases" 대한장연구학회 18 (18): 18-33, 2020